Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction

E

EGBOT

Guest
Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction

HTML:
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.

Source: Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction
 

Create an account or login to comment

You must be a member in order to leave a comment

Create account

Create an account on our community. It's easy!

Log in

Already have an account? Log in here.

Latest threads

Back
Top